OrganaBio Acquires Excellos Operating Assets, Creating a Bicoastal Cell Therapy CTDMO
May 13, 2026
OrganaBio acquired substantially all of the operating assets of San Diego-based Excellos Inc. to establish a bicoastal cell therapy contract testing, development and manufacturing organization (CTDMO). The deal retains the core Excellos team and creates Excellos Labs, an OrganaBio subsidiary, expanding redundancy and geographic coverage for cell therapy services including PBMC isolation and cryopreservation.
- Buyers
- OrganaBio, LLC
- Targets
- Excellos Inc.
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ABL Diagnostics Selected by Évry Commercial Court to Acquire TEXCELL’s Operations
July 24, 2026
Healthcare Services
ABL Diagnostics said it has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL. The deal involves the transfer of 29 employees and the continuation of TEXCELL’s operations at the Genopole site in Évry-Courcouronnes, strengthening ABL Diagnostics’ virology and biosafety capabilities for biopharmaceutical customers.
-
GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions
May 8, 2026
Healthcare Services
GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.
-
Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business
February 23, 2026
Biotechnology
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.
-
Artis BioSolutions Acquires Landmark Bio
April 2, 2025
Biotechnology
Artis BioSolutions, a newly launched CDMO backed by Oak HC/FT, has acquired Landmark Bio to expand capabilities for the development and manufacturing of cell and gene therapies. Landmark Bio will continue to operate as a distinct entity from its Watertown, Massachusetts headquarters while leveraging Artis' funding and platform to scale process development, GMP manufacturing, and commercialization support.
-
PerkinElmer Acquires Nexcelom Bioscience for $260M
May 13, 2021
Medical Devices
PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.
-
Lonza AG Acquires PharmaCell BV
June 1, 2017
Biotechnology
Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.